SE9604341D0 - Hepta-peptide oxytocin analogue - Google Patents

Hepta-peptide oxytocin analogue

Info

Publication number
SE9604341D0
SE9604341D0 SE9604341A SE9604341A SE9604341D0 SE 9604341 D0 SE9604341 D0 SE 9604341D0 SE 9604341 A SE9604341 A SE 9604341A SE 9604341 A SE9604341 A SE 9604341A SE 9604341 D0 SE9604341 D0 SE 9604341D0
Authority
SE
Sweden
Prior art keywords
pct
moiety
hepta
aminoacid
analogues
Prior art date
Application number
SE9604341A
Other languages
English (en)
Swedish (sv)
Inventor
Per Melin
Anders Nilsson
Jerzy Trojnar
Carl-Johan Aurell
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Priority to SE9604341A priority Critical patent/SE9604341D0/xx
Publication of SE9604341D0 publication Critical patent/SE9604341D0/xx
Priority to BRPI9713366-3A priority patent/BR9713366B1/pt
Priority to IL12951997A priority patent/IL129519A/en
Priority to JP52460298A priority patent/JP3405460B2/ja
Priority to TR1999/01028T priority patent/TR199901028T2/xx
Priority to PT97946210T priority patent/PT938496E/pt
Priority to SI9720076A priority patent/SI20026B/sl
Priority to SK704-99A priority patent/SK283800B6/sk
Priority to US09/308,912 priority patent/US6143722A/en
Priority to CZ0183299A priority patent/CZ299532B6/cs
Priority to EEP199900210A priority patent/EE03832B1/xx
Priority to NZ336445A priority patent/NZ336445A/en
Priority to RO99-00593A priority patent/RO120772B1/ro
Priority to HR970630A priority patent/HRP970630B1/xx
Priority to KR10-1999-7004449A priority patent/KR100463132B1/ko
Priority to AU51429/98A priority patent/AU713424B2/en
Priority to UA99042410A priority patent/UA54459C2/uk
Priority to PL97333876A priority patent/PL189292B1/pl
Priority to CN97180014A priority patent/CN1129606C/zh
Priority to EP97946210A priority patent/EP0938496B1/en
Priority to ZA9710518A priority patent/ZA9710518B/xx
Priority to DE69722651T priority patent/DE69722651T2/de
Priority to AT97946210T priority patent/ATE242264T1/de
Priority to HK00101422.6A priority patent/HK1022481B/xx
Priority to CA002272990A priority patent/CA2272990C/en
Priority to DK97946210T priority patent/DK0938496T3/da
Priority to ES97946210T priority patent/ES2203823T3/es
Priority to RU99113364/04A priority patent/RU2180668C2/ru
Priority to HU0000577A priority patent/HU228568B1/hu
Priority to PCT/SE1997/001968 priority patent/WO1998023636A1/en
Priority to MYPI97005691A priority patent/MY125555A/en
Priority to ARP970105543A priority patent/AR008531A1/es
Priority to LVP-99-77A priority patent/LV12350B/en
Priority to LT99-052A priority patent/LT4650B/lt
Priority to NO19992532A priority patent/NO321380B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SE9604341A 1996-11-26 1996-11-26 Hepta-peptide oxytocin analogue SE9604341D0 (sv)

Priority Applications (35)

Application Number Priority Date Filing Date Title
SE9604341A SE9604341D0 (sv) 1996-11-26 1996-11-26 Hepta-peptide oxytocin analogue
PCT/SE1997/001968 WO1998023636A1 (en) 1996-11-26 1997-11-21 Heptapeptide oxytocin analogues
UA99042410A UA54459C2 (uk) 1996-11-26 1997-11-21 Аналоги гептапептиду окситоцину, спосіб їх отримання, фармацевтична композиція, спосіб її отримання, спосіб запобігання передчасним пологам
PL97333876A PL189292B1 (pl) 1996-11-26 1997-11-21 Analog heptapeptydowy, środek farmacetyczny zawierający ten analog, zastosowanie analogu, zastosowanie środka farmacetycznego, sposób wytwarzania tego analogu oraz sposób wytwarzania środka farmacetycznego
JP52460298A JP3405460B2 (ja) 1996-11-26 1997-11-21 ヘプタペプチドオキシトシン類似体
TR1999/01028T TR199901028T2 (xx) 1996-11-26 1997-11-21 Heptapeptid oksitosin analoglar�.
PT97946210T PT938496E (pt) 1996-11-26 1997-11-21 Misturas insecticidas sinergicas
SI9720076A SI20026B (sl) 1996-11-26 1997-11-21 Heptapeptidni analogi - antagonisti oksitocina
SK704-99A SK283800B6 (sk) 1996-11-26 1997-11-21 Heptapeptidový analóg, farmaceutická kompozícia obsahujúca tento analóg, spôsob prípravy heptapeptidového analógu a jeho použitie pri príprave liečiva na redukciu alebo blokovanie kontrakcie maternicového svalu
US09/308,912 US6143722A (en) 1996-11-26 1997-11-21 Heptapeptide oxytocin analogues
CZ0183299A CZ299532B6 (cs) 1996-11-26 1997-11-21 Heptapeptidový analog, farmaceutická kompozice obsahující tento analog, zpusob prípravy heptapeptidového analogu a jeho použití a zpusob prípravy farmaceutické kompozice obsahující tento analog
EEP199900210A EE03832B1 (et) 1996-11-26 1997-11-21 Heptapeptiidanaloogid
EP97946210A EP0938496B1 (en) 1996-11-26 1997-11-21 Heptapeptide oxytocin analogues
RO99-00593A RO120772B1 (ro) 1996-11-26 1997-11-21 Analogi de heptapeptidă, compoziţie farmaceutică care îi conţine şi procedeu de preparare a acestora
HR970630A HRP970630B1 (en) 1996-11-26 1997-11-21 Hepapeptide oxytocin analogues
KR10-1999-7004449A KR100463132B1 (ko) 1996-11-26 1997-11-21 헵타펩티드 옥시토신 동족체
AU51429/98A AU713424B2 (en) 1996-11-26 1997-11-21 Heptapeptide oxytocin analogues
BRPI9713366-3A BR9713366B1 (pt) 1996-11-26 1997-11-21 análogos de heptapeptìdeo oxitocina.
CN97180014A CN1129606C (zh) 1996-11-26 1997-11-21 七肽催产素类似物
IL12951997A IL129519A (en) 1996-11-26 1997-11-21 Potateptide analogues with antagonistic activity to oxytocin, their preparation methods, pharmaceutical compositions containing them, and their use in the manufacture of drugs
NZ336445A NZ336445A (en) 1996-11-26 1997-11-21 Heptapeptide oxytocin analogues
ZA9710518A ZA9710518B (en) 1996-11-26 1997-11-21 Oxytocin heptapeptide analogues.
DE69722651T DE69722651T2 (de) 1996-11-26 1997-11-21 Heptapeptid oxytocin analogen
AT97946210T ATE242264T1 (de) 1996-11-26 1997-11-21 Heptapeptid oxytocin analogen
HK00101422.6A HK1022481B (en) 1996-11-26 1997-11-21 Heptapeptide oxytocin analogues
CA002272990A CA2272990C (en) 1996-11-26 1997-11-21 Heptapeptide oxytocin analogues
DK97946210T DK0938496T3 (da) 1996-11-26 1997-11-21 Heptapeptidoxytocinanaloger
ES97946210T ES2203823T3 (es) 1996-11-26 1997-11-21 Analogos heptapeptidicos de oxitocina.
RU99113364/04A RU2180668C2 (ru) 1996-11-26 1997-11-21 Гептапептидные аналоги окситоцина
HU0000577A HU228568B1 (en) 1996-11-26 1997-11-21 Heptapeptide oxytocin analogues pharmaceutical compositions containing them and their use and for producing them
MYPI97005691A MY125555A (en) 1996-11-26 1997-11-25 Heptapeptide oxytocin analogues
ARP970105543A AR008531A1 (es) 1996-11-26 1997-11-26 Análogos a heptapeptidos antagonistas de la oxitocina
LVP-99-77A LV12350B (en) 1996-11-26 1999-04-30 HEPTAPEPHITE OXITOCIN ANALOGUE
LT99-052A LT4650B (lt) 1996-11-26 1999-05-11 Heptapeptidiniai oksitocino analogai
NO19992532A NO321380B1 (no) 1996-11-26 1999-05-26 Heptapeptid analog med oksytocinantagonistaktivitet, fremgangsmate ved fremstilling derav samt anvendelse derav til fremstilling av medikamenter.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9604341A SE9604341D0 (sv) 1996-11-26 1996-11-26 Hepta-peptide oxytocin analogue

Publications (1)

Publication Number Publication Date
SE9604341D0 true SE9604341D0 (sv) 1996-11-26

Family

ID=20404757

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9604341A SE9604341D0 (sv) 1996-11-26 1996-11-26 Hepta-peptide oxytocin analogue

Country Status (34)

Country Link
US (1) US6143722A (cs)
EP (1) EP0938496B1 (cs)
JP (1) JP3405460B2 (cs)
KR (1) KR100463132B1 (cs)
CN (1) CN1129606C (cs)
AR (1) AR008531A1 (cs)
AT (1) ATE242264T1 (cs)
AU (1) AU713424B2 (cs)
BR (1) BR9713366B1 (cs)
CA (1) CA2272990C (cs)
CZ (1) CZ299532B6 (cs)
DE (1) DE69722651T2 (cs)
DK (1) DK0938496T3 (cs)
EE (1) EE03832B1 (cs)
ES (1) ES2203823T3 (cs)
HR (1) HRP970630B1 (cs)
HU (1) HU228568B1 (cs)
IL (1) IL129519A (cs)
LT (1) LT4650B (cs)
LV (1) LV12350B (cs)
MY (1) MY125555A (cs)
NO (1) NO321380B1 (cs)
NZ (1) NZ336445A (cs)
PL (1) PL189292B1 (cs)
PT (1) PT938496E (cs)
RO (1) RO120772B1 (cs)
RU (1) RU2180668C2 (cs)
SE (1) SE9604341D0 (cs)
SI (1) SI20026B (cs)
SK (1) SK283800B6 (cs)
TR (1) TR199901028T2 (cs)
UA (1) UA54459C2 (cs)
WO (1) WO1998023636A1 (cs)
ZA (1) ZA9710518B (cs)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
US6476072B1 (en) * 2000-11-21 2002-11-05 Arthur Vanmoor Method of treating menstrual pain by enhancing the effectiveness of the human immune system
JP4615221B2 (ja) * 2002-02-27 2011-01-19 フェリング ベスローテン フェンノートシャップ ヘプタペプチドオキシトシンアナログを製造するための中間体及び方法
US20060014147A1 (en) * 2002-05-02 2006-01-19 Stefan Golz Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr)
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
UA76639C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
ATE301990T1 (de) * 2003-07-25 2005-09-15 Ferring Bv Pharmazeutische desmopressin-zubereitung als feste darreichungsform und methode zu ihrer herstellung
ES2260563T3 (es) * 2003-11-13 2006-11-01 Ferring B.V. Paquete de blister y forma farmaceutica solida para ello.
EP1555029A1 (en) 2004-01-19 2005-07-20 Ferring B.V. Use of substances having oxytocin antagonistic properties for the preparation of a medicament for treating hypertension
US20060171909A1 (en) * 2005-02-03 2006-08-03 The Procter & Gamble Company Cosmetic compositions comprising colorants with low free dye
SE528446C2 (sv) * 2006-03-02 2006-11-14 Ferring Int Ct Sa Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse
KR20140143461A (ko) 2007-08-06 2014-12-16 알레간 인코포레이티드 데스모프레신 약물 전달을 위한 방법 및 장치
DK2260053T3 (da) * 2008-03-31 2014-06-23 Ferring Bv Oxytocin-analoger
SI2712622T1 (sl) 2008-05-21 2016-10-28 Ferring B.V. Orodisperzibilni dezmopresin za povečanje začetnega obdobja spanja nemotenega z nokturijo
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
TWI463990B (zh) * 2009-09-21 2014-12-11 Ferring Bv 催產素受體促進劑
EA030566B1 (ru) 2010-07-15 2018-08-31 Олег Ильич ЭПШТЕЙН Способ повышения терапевтической эффективности активированной-потенцированной формы антитела к эндогенной биомолекуле и фармацевтическая композиция
JO3400B1 (ar) * 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
EP2684888B1 (en) 2011-03-09 2019-05-15 Jitsubo Co., Ltd. Novel cross-linked peptides containing non-peptide cross-linked structure, method for synthesizing cross-linked peptides, and novel organic compound used in method
CN102875650B (zh) * 2012-09-26 2014-06-11 深圳翰宇药业股份有限公司 巴卢西班的制备方法
US9365615B2 (en) 2013-09-09 2016-06-14 Jitsubo Co., Ltd. Cross-linked peptides containing non-peptide cross-linked structure, method for synthesizing cross-linked peptides, and novel organic compound used in method
PL3037101T3 (pl) 2014-12-22 2019-06-28 Ferring B.V. Terapia antagonistą receptora oksytocyny w fazie lutealnej w celu implantacji i uzyskania ciąży u kobiet poddawanych technikom wspomaganego rozrodu
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
JP2018535946A (ja) 2015-10-06 2018-12-06 フェリング・ベー・フェー バルシバン及びその中間体を作製する新規の方法
ES2915948T3 (es) 2016-01-04 2022-06-27 ObsEva SA Administración conjunta de alfa-aminoéster de derivado de hidroxipropiltiazolidin-carboxamida y un agente tocolítico
WO2018015497A2 (en) 2016-07-21 2018-01-25 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
EP4025207A1 (en) 2019-09-03 2022-07-13 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
AU2021218895A1 (en) 2020-02-10 2022-09-15 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ279654B6 (cs) * 1987-12-21 1995-05-17 Sandoz Ag Způsob výroby cyklosporinu A
US5373089A (en) * 1988-09-02 1994-12-13 Northwestern University Oxytocin antagonist
CA2036973A1 (en) * 1990-02-27 1991-08-28 Mark G. Bock Cyclic hexapeptide oxytocin antagonists
SE9002384D0 (sv) * 1990-07-09 1990-07-09 Ferring Ab Derivat av baklobshormoner
DE4022247A1 (de) * 1990-07-12 1992-01-16 Hoechst Ag Verfahren zur extraktiven abtrennung von 2-alkylthio-5-phenylpyrimidinen aus ihren reaktionsgemischen
SE501678C2 (sv) * 1993-07-13 1995-04-10 Ferring Bv Peptid med oxytocinantagonistaktivitet samt farmaceutisk komposition innehållande nämnda peptid
SE523819C2 (sv) 1994-01-27 2004-05-18 Per-Ingvar Nilsson Accelerationsmunstycke samt metod för dess användning
SE9400918L (sv) 1994-03-18 1995-09-19 Anne Fjellstad Paulsen Stabiliserad komposition för oral administrering av peptider
SE9500249L (sv) 1995-01-25 1996-03-25 Valeo Engine Cooling Ab Värmeväxlartank med ändstycken, förfarande för framställning av en sådan tank, samt värmeväxlare försedd med en sådan

Also Published As

Publication number Publication date
PL189292B1 (pl) 2005-07-29
CA2272990A1 (en) 1998-06-04
KR100463132B1 (ko) 2004-12-23
NO992532D0 (no) 1999-05-26
SK70499A3 (en) 2000-10-09
EE03832B1 (et) 2002-08-15
WO1998023636A1 (en) 1998-06-04
HUP0000577A2 (hu) 2000-11-28
EE9900210A (et) 1999-12-15
CN1238781A (zh) 1999-12-15
SI20026A (sl) 2000-02-29
CZ299532B6 (cs) 2008-08-27
LV12350B (en) 1999-11-20
DK0938496T3 (da) 2003-10-06
NZ336445A (en) 2000-06-23
LT4650B (lt) 2000-04-25
PT938496E (pt) 2003-10-31
RO120772B1 (ro) 2006-07-28
CA2272990C (en) 2002-11-19
HU228568B1 (en) 2013-04-29
NO992532L (no) 1999-05-26
AU713424B2 (en) 1999-12-02
ZA9710518B (en) 1998-06-10
LV12350A (lv) 1999-09-20
IL129519A (en) 2004-09-27
NO321380B1 (no) 2006-05-02
ATE242264T1 (de) 2003-06-15
BR9713366B1 (pt) 2010-05-18
TR199901028T2 (xx) 1999-07-21
MY125555A (en) 2006-08-30
DE69722651T2 (de) 2004-04-08
HRP970630A2 (en) 1998-10-31
EP0938496A1 (en) 1999-09-01
JP2000507617A (ja) 2000-06-20
DE69722651D1 (en) 2003-07-10
EP0938496B1 (en) 2003-06-04
US6143722A (en) 2000-11-07
CZ183299A3 (cs) 2000-05-17
HK1022481A1 (en) 2000-08-11
SI20026B (sl) 2000-06-30
JP3405460B2 (ja) 2003-05-12
RU2180668C2 (ru) 2002-03-20
SK283800B6 (sk) 2004-02-03
AU5142998A (en) 1998-06-22
UA54459C2 (uk) 2003-03-17
LT99052A (en) 2000-01-25
AR008531A1 (es) 2000-01-19
CN1129606C (zh) 2003-12-03
HUP0000577A3 (en) 2001-02-28
HRP970630B1 (en) 2002-04-30
IL129519A0 (en) 2000-02-29
BR9713366A (pt) 2000-01-25
KR20000069045A (ko) 2000-11-25
ES2203823T3 (es) 2004-04-16

Similar Documents

Publication Publication Date Title
MY125555A (en) Heptapeptide oxytocin analogues
MX9801716A (es) Derivados de meta-guanidina, urea, tiourea o acido aminobenzoico azaciclico, como antagonistas de integrina.
TW363064B (en) Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors
DK0894084T3 (da) Kanelsyrederivater og deres anvendelse som integrinantagonister
ES2162676T3 (es) Derivados de fenileno sustituidos en meta y su uso como antagonistas o inhibidores de integrina alfav,beta3.
ATE260658T1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
ES2158537T3 (es) Derivados de acidos ciclopropilalcanoicos.
HUP9901209A2 (hu) Opioid analóg peptid vegyületek, eljárás előállításukra és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
MC2326A1 (fr) Antagonistes d'un nonapeptide de la bombesine
ATE245435T1 (de) Totalsynthese des amino hip analogen von didemnin a
NO944293D0 (no) Bombesin antagonist-polypeptider
ATE254121T1 (de) Heterocyclische verbindungen als bradykinin antagonisten
ATE125548T1 (de) Peptide.
MX9201055A (es) N-[[4,5-dihidroxi- y 4,5,8-trihidroxi-9,10-dihidro-9,10-dioxo-2-antracen-il] carbonil] aminoacidos utiles en la terapia de afecciones osteoarticulares.
DE69119409D1 (de) Vasoaktive derivate des vasotocins
SE9800865D0 (sv) New Process
Natarajan et al. Ketomethylureas. A new class of angiotensin converting enzyme inhibitors